| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/11/2002 | EP1165122B1 Use of molecular weight-amplified hirudin as an anticoagulant in extracorporeal renal replacement therapy |
| 09/11/2002 | EP1100463B1 New injectable formulations containing ramoplanin |
| 09/11/2002 | EP1079838B1 Edelfosin for the treatment of brain tumours |
| 09/11/2002 | EP1067936B1 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
| 09/11/2002 | EP1047732B1 Color shifting film glitter |
| 09/11/2002 | EP1047409B1 Tts containing an antioxidant |
| 09/11/2002 | EP1003490B1 Transdermal therapeutic system (tts) for administering sexual steroid hormones |
| 09/11/2002 | EP0971704B1 Comestible capsules having flavoured coatings |
| 09/11/2002 | EP0930873B1 Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
| 09/11/2002 | EP0910399B1 Stable pharmaceutical composition of bdnf |
| 09/11/2002 | EP0871467B1 Formulation for peptide release |
| 09/11/2002 | EP0769942B1 Use of a cationic amphipathic compound as a transfection agent, vaccine additive or drug |
| 09/11/2002 | EP0757910B1 Percutaneously administrable base composition and percutaneously administrable drug composition prepared therefrom |
| 09/11/2002 | EP0665010B1 Method of manufacturing wax matrices |
| 09/11/2002 | CN1368892A Sustained release formulation of peptide |
| 09/11/2002 | CN1368891A Moxilfloxacin formulation containing common salt |
| 09/11/2002 | CN1368890A Edible holographic products particularly pharmaceuticals and methods and apparatus for producing same |
| 09/11/2002 | CN1368889A Ocular tension lowering composition for topical admistration |
| 09/11/2002 | CN1368887A Mycophenolate Mofetil in association with PEG-IFN alpha |
| 09/11/2002 | CN1368885A Compositions and methods for identifying antigens which elicit an immune response |
| 09/11/2002 | CN1368880A Water-miscible pharmaceutical compositions of paclitaxel |
| 09/11/2002 | CN1368877A Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same |
| 09/11/2002 | CN1368876A Compositions and methods of treatment of attention deficit disorder and attention dificit/hyperactivity disorder with methylphenidate |
| 09/11/2002 | CN1368874A Implantable active ingredient depot |
| 09/11/2002 | CN1090478C Preparations |
| 09/11/2002 | CN1090477C Ibuprofen containing solid composition |
| 09/11/2002 | CN1090476C Sterile ophthalmological gel propn. applicable in drops and process for producing it |
| 09/11/2002 | CN1090459C Stabilized composition comprising colistin sulfate |
| 09/10/2002 | US6448380 Complexing |
| 09/10/2002 | US6448378 Made by preparing a purified solution of monoreactive-amine modified collagen, such as glutaric anhydride derivatized collagen, heating to reduce viscosity and adding the drug to the solution, casting into thin layers, drying into film |
| 09/10/2002 | US6448323 A plasticizer such as polyethylene glycol or glycerin, talc, and preferably a pigment/opacifier and lecithin for coating pharmaceutical tablets, foods, candies, seeds etc. |
| 09/10/2002 | US6448303 High molecular weight rubber and less than about 60 parts by weight of a liquid diluent, and having a g' of less than about 15 x 104 dynes/cm2 at 10 rad/s at 25 degrees c. |
| 09/10/2002 | US6448296 Aqueous suspension with good redispersibility |
| 09/10/2002 | US6448225 Human growth hormone aqueous formulation |
| 09/10/2002 | US6448093 Solubilization of hyaluronic acid in aqueous solution of electrolyte and acid; solubilization of polar substancec (i.e. a plasmid) in mixture; acidification; dialyzing said mixture to reduce an ionic concentration past point of collapse |
| 09/10/2002 | US6448083 Contacting a mammalian cell with filamentous phage particles presenting a ligand on their surfaces, wherein a vector within the phage encodes a gene product under control of a promoter |
| 09/10/2002 | US6447819 Water-soluble complex of an extract of Ginkgo biloba, process for the preparation thereof and composition comprising the same |
| 09/10/2002 | US6447814 Plant extracts used for prevention of cardiovascular disorders, obtained by solvent extraction, heating, filtration and condensation, then encapsulation to form particles; side effect reduction |
| 09/10/2002 | US6447803 Containing addition polymer |
| 09/10/2002 | US6447782 Lipid extract of the Skeletonema algae |
| 09/10/2002 | US6447776 Monoclonal antibodies against mutant amino acid sequences generated by genetic deletions or point mutations; detection of cancer |
| 09/10/2002 | CA2288375C Novel pulmonary surfactants and therapeutic uses, including pulmonary lavage |
| 09/10/2002 | CA2260852C Pleasant-tasting aqueous liquid composition of a bitter-tasting drug |
| 09/06/2002 | WO2002069232A2 Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| 09/06/2002 | WO2002069198A2 Hla ligand database utilizing predictive algorithms and methods of making and using same |
| 09/06/2002 | WO2002068676A2 METHODS AND COMPOSITIONS FOR MODIFYING APOLIPOPROTEIN B mRNA EDITING |
| 09/06/2002 | WO2002068562A2 Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| 09/06/2002 | WO2002068561A2 Cubic liquid crystalline phase precursor |
| 09/06/2002 | WO2002068518A1 Antibacterial and fungicidal polymer dispersions and polymer solutions |
| 09/06/2002 | WO2002068451A2 Sperm protein 17 for the diagnosis and treatment of cancer |
| 09/06/2002 | WO2002068111A1 Process for making microcapsules involving phase inversion |
| 09/06/2002 | WO2002068000A2 Polymeric imagable brachytherapy seed |
| 09/06/2002 | WO2002067998A2 Devices and methods for the treatment of cancer |
| 09/06/2002 | WO2002067995A1 Carrier systems comprising vitamin b12 - biodegradable micro particulate conju gates for peroral delivery of drugs, peptides/proteins and vaccines |
| 09/06/2002 | WO2002067994A2 Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same |
| 09/06/2002 | WO2002067992A2 Drug compositions having enhanced solubility |
| 09/06/2002 | WO2002067991A1 Erodible polymers for injection |
| 09/06/2002 | WO2002067990A1 Polynucleotide formulation for enhanced intracellular transfer |
| 09/06/2002 | WO2002067989A1 Crystallisation-resistant aqueous growth hormone formulations |
| 09/06/2002 | WO2002067977A1 Eye drops |
| 09/06/2002 | WO2002067973A1 Compositions and methods for protecting tissues and cells from damage, and for repairing damaged tissues |
| 09/06/2002 | WO2002067971A2 Use of endostatin in the treatment of ocular neovascularization |
| 09/06/2002 | WO2002067952A1 Prophylactic teat treatment |
| 09/06/2002 | WO2002067951A2 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases |
| 09/06/2002 | WO2002067943A1 Oral pharmaceutical composition of cefpodoxime proxetil |
| 09/06/2002 | WO2002067935A1 A stable pharmaceutical formulation comprising torsemide modification ii |
| 09/06/2002 | WO2002067917A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 09/06/2002 | WO2002067916A2 Pharmaceutical salts |
| 09/06/2002 | WO2002067908A1 Novel dendritic polymers and their biomedical uses |
| 09/06/2002 | WO2002067907A1 Compositions and methods for preventing platelet aggregation |
| 09/06/2002 | WO2002067906A1 Coating and binding agent for pharmaceutical formulations with improved storage stability |
| 09/06/2002 | WO2002067904A1 Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer |
| 09/06/2002 | WO2002067903A2 Compositions and methods of manufacture for oral dissolvable dosage forms |
| 09/06/2002 | WO2002067902A2 Modulation of release from dry powder formulations |
| 09/06/2002 | WO2002067901A1 Fibrate-statin combinations with reduced fed-fasted effects |
| 09/06/2002 | WO2002067900A1 Multi-lamellar emulsion(mle) for stabilizing dermatologically useful ingredients and external base preparations for general skin diseases utilizing the same |
| 09/06/2002 | WO2002067899A1 Injectable water-in-oil emulsions |
| 09/06/2002 | WO2002067898A1 Prolongation of chemical activity of flavorants and therapeutics with cetyl pyridinium chloride |
| 09/06/2002 | WO2002067897A2 In-situ gel formation of pectins |
| 09/06/2002 | WO2002067895A2 Implant dosage form and use thereof for the delivery of a cholesterol lowering agent |
| 09/06/2002 | WO2002067894A2 Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors |
| 09/06/2002 | WO2002067893A2 Pharmaceutical formulation comprising bicalutamide |
| 09/06/2002 | WO2002067859A2 Ascorbic acid analogs for metalloradiopharmaceuticals |
| 09/06/2002 | WO2002067857A2 Modified annexin proteins and methods for preventing thrombosis |
| 09/06/2002 | WO2002067850A2 B/b-like fragment targeting for the purposes of photodynamic therapy and medical imaging |
| 09/06/2002 | WO2002067831A1 Composition for freshening nostrils and sinus cavities |
| 09/06/2002 | WO2002067761A2 Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque |
| 09/06/2002 | WO2002067683A1 Hiv protease inhibitors supported on cation exchange resins for oral administration |
| 09/06/2002 | WO2002067651A2 Pharmaceutical salts |
| 09/06/2002 | WO2002055089A3 Immunoassay technique using multispecific molecules |
| 09/06/2002 | WO2002055059A3 Method for preparing submicron particle suspensions |
| 09/06/2002 | WO2002047659A3 Preparation of drug particles using evaporation precipitation into aqueous solutions |
| 09/06/2002 | WO2002045691A3 Laboratory scale milling process |
| 09/06/2002 | WO2002043708A3 Magnetic particles for the targeted regional therapy |
| 09/06/2002 | WO2002040062A3 Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative |
| 09/06/2002 | WO2002036771A3 Imaging, diagnosis and treatment of disease |
| 09/06/2002 | WO2002024185A3 Topical analgesic compositions containing aliphatic polyamines and methods of using same |
| 09/06/2002 | WO2002024149A3 Immunogen comprising ligand bound hiv envelpe protein |
| 09/06/2002 | WO2002023995A8 Method of blocking free radical processes which result in media ted pathology without deleterious pro-oxidant side reactions |
| 09/06/2002 | WO2002019972A3 Stabilized ascorbic acid solutions |